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The etiology of many severe childhood movement disorders remains uncharacterized. 
We describe a novel neurological disorder with prominent hyperkinetic movements in both mice 
and humans caused by mutations in FRRS1L, an AMPA receptor outer core protein. Loss of 
FRRS1L function attenuates AMPA-mediated currents, implicating chronic abnormalities of 
glutamatergic neurotransmission in this monogenic neurological disease of childhood.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Pediatric movement disorders encompass a heterogeneous group of 
neurodevelopmental and neurodegenerative disorders affecting movement and limiting activities 
of daily living (1). Huntington disease (HD) is a progressive neurodegenerative disease 
characterized by impairment of volitional movement, chorea and subcortical dementia due to a 
CAG triplet repeat expansion in HTT. Although uncommon, juvenile HD (JHD) represents an 
important cause of pediatric movement disorders (2). Although the majority of patients with 
clinical features of HD will ultimately be found to have an expanded HTT allele, several 
phenocopies have been described, yet the cause of most HD-like syndromes remains 
uncharacterized (3). We set out to identify genes that lead to HD-like phenotypes and enrolled 
eligible families in our institutional review board and ethics committee-approved studies after 
informed consent was obtained.  
 
The index family hailed from southern Saudi Arabia, and the parents were distant 
cousins (Supplementary Figure 1a). All five of the couple’s children developed progressive 
chorea, dementia and epilepsy without expansion of HTT (Supplementary Table 1). Over time, 
a rigid, akinetic presentation began to predominate. One child had already succumbed to the 
disease at the time of ascertainment. All laboratory studies were unrevealing. Brain MRI was 
initially normal, but repeat neuroimaging demonstrated diffuse cortical and cerebellar volume 
loss with flattening of the caudate heads (Supplementary Figure 1b).  
 
Given the family structure and presumed autosomal recessive nature of the disorder, we 
then applied tandem homozygosity mapping and whole exome sequencing. We identified six 
regions of homozygosity >3 Mb shared by affected family members alone (Supplementary 
Table 2). We performed whole exome sequencing on patients 1_II:-1-4 and focused our 
analysis on homozygous stop-gain, stop-loss, or frameshift and splice-site or missense variants 
predicted to be deleterious. We excluded variants with a reported minor allele frequency >0.01 
based on ExAc Browser and Exome Variant Server databases. Using this strategy, we identified 
a homozygous c.961C>T (p.G321*) mutation in FRRS1L (aka c9orf4) (NM_014334) within a 
prominent block of homozygosity (hg19; chr9:104,622,396-119,149,440). We confirmed 
segregation within affected family members by Sanger sequencing (Supplementary Figure 
1a). This mutation has not been reported in variation repositories, and is predicted to lead to 
loss of a C-terminal hydrophobic motif that may contribute to FRRS1L’s membrane localization 
(Figure 1a). 
 
 We subsequently identified three additional, unrelated patients with similar phenotypes 
(Supplemental Video 1) by whole exome sequencing [patient 2_II-1: homozygous c.845G>A 
(p.W282*)]; patient 3_II-1: homozygous c.737_739del (p.G246del)]; patient 4_II-2 c.436dup; 
(p.Ile146Asnfs*10) (Supplementary Table 1) and confirmed mutations by Sanger sequencing 
(Supplementary Figure 1a). None of these variants has been identified in public repositories. 
Targeted sequencing of FRRS1L in a cohort of 52 pediatric and adult patients with an early-
onset Huntington-like phenotype but without demonstrable mutations in HTT did not reveal any 
putatively pathogenic biallelic mutations (Supplementary Table 3). Additionally, no biallelic 
FRRS1L mutations were detected in the Epi4K and EuroEPINOMICS RES epilepsy consortia 
datasets.  
 
 Using patient fibroblasts and age and sex-matched controls, we next performed RT-PCR 
to determine whether the c.961C>T and c.845G>A mRNAs are subject to nonsense-mediated 
decay. Although FRRS1L is predominantly expressed in the brain (Supplementary Figure 2a), 
it is expressed at a lower level in fibroblasts (4) (Figure 1b). For both c.961C>T and c.845G>A, 
consistent with a mutation location near the 3’ end of the transcript, we found equal levels of 
both control and mutant transcripts (Supplementary Figure 2b). Both the (p.G321*) and 
(p.W282*) patient fibroblasts exhibited a marked decrease in FRRS1L levels by immunoblot 
(Figure 1b).  
 
Little is known about the biological function of FRRS1L. Despite its name (ferric chelate 
reductase-like 1), it lacks a ferrochelatase domain, and so is unlikely to function in iron storage 
and processing. A recent study instead identified FRRS1L as an important component of the 
outer core of AMPA glutamate receptor accessory proteins (5), suggesting that loss of FRRS1L 
would affect AMPA receptor constituency and might affect AMPA receptor function. In that 
study, FRRS1L co-immunoprecipitated with GluR1, suggesting a direct interaction between the 
two proteins. In order to study the effect(s) of FRRS1L loss of function, we first sought to 
determine the normal localization of FRRS1L and characterize interactions with AMPA 
receptors. Using mouse primary neurons, we found high FRRS1L expression at the plasma 
membrane and in agreement with the prior proteomics study, the protein co-localizes with 
AMPA receptors on the neuronal surface (Figure 1c). However, the identification of widespread 
GluR1-containing AMPA receptors lacking FRRS1L co-localization suggests that FRRS1L is 
likely found in only a subset of AMPA receptors. These findings are not surprising, as recent 
work has highlighted the remarkable molecular diversity of glutamate receptors (6).  
 
We sought to determine whether the loss of the transmembrane-association motif 
(residues 322-342) would lead to altered localization in (p.G321*) and (p.W282*) patient cells. 
We found diminished co-localization with AMPA receptors at the cell surface membrane 
demonstrable by total internal reflectance microscopy (TIRF) (Figure 1d).  
 
 We next sought to determine how the loss of FRRS1L seen in our patients could affect 
AMPA receptor function. Using neuronally-differentiated SH5Y-SY cells, we knocked down 
FRRS1L using siRNA, leading to a reduction in FRRS1L levels similar to that seen in patient 
cells (Supplementary Figure 3). We next performed a series of patch-clamp experiments with 
a focus on AMPA-mediated currents. We found that loss of FRRS1L significantly attenuated 
calcium influx (Figure 1e,f) and diminished AMPA-induced inward currents (Figure 1g-i). 
 
In parallel with the human studies, a Frrs1l null mouse (Frrs1lTm1b/Tm1b) was generated as 
part of the International Mouse Phenotyping Consortium by homologous recombination followed 
by excision of the Neo cassette (Supplementary Figure 4a). Loss of Frrs1l was confirmed by 
both sequence analysis and western blot (Supplementary Figure 4b,c). Similar to human 
patients with homozygous mutations, null mice exhibited disordered hyperkinetic movements 
from a young age (Supplemental Video 2a,b).  
Phenotypic characterization of Frrs1lTm1b/Tm1b animals revealed both evidence of 
neuromotor dysfunction (Figure 2a) as well as impaired volitional movement (Figure 2b). Both 
of these features are very similar to those observed in human FRRS1L patients. Although no 
spontaneous seizures were observed in Frrs1lTm1b/Tm1b mice, early death occurred (Figure 2c), 
indicating postnatal demise. Necropsy analysis of these animals did not reveal an evident cause 
of death. Neuropathological analysis of knockout animals at age 16 weeks showed 
morphologically normal brains (Supplementary Figure 5), as seen in early MRIs in human 
patients.  
 We next evaluated Frrs1l expression in embryos and adult mice using a lacZ reporter. In 
E12.5 embryos, Frrs1l expression was evident in the ventral forebrain but lower level expression 
was seen in the remainder of the embryo while Frrs1l expression was highest in the adult brain 
in the cortex, cerebellum, hippocampus, and basal ganglia (Supplementary Figure 2a). This is 
consistent with prior reports which indicated robust expression in multiple brain regions, 
including striatum, thalamus, and cortex (7, 8). Developmentally, Frrs1l may play a role in 
neuronal maturation, as AMPA receptors promote the formation and maturation of synapses 
during development (9).   
 Our findings implicate FRRS1L as an important modulator of glutamate signaling with 
substantial implications in health and disease. AMPA receptors mediate fast excitatory 
postsynaptic potentials (EPSCs) in the human brain. EPSCs in turn are largely mediated by 
inwardly directed Ca2+ currents at the postsynaptic spine. AMPA receptor complexity is only now 
beginning to be appreciated, as dozens of auxiliary subunits govern ion channel gating 
properties, and dynamic changes in AMPA receptor composition are likely to affect localization 
and abundance within the synapse (10-12). FRRS1L is an outer core protein that is thought to 
function within the AMPA receptor and directly interact with inner core components, as 
illustrated by the ability to immunoprecipitate FRRS1L after GluR1/2 pull-down (5). The 
significant diminution of AMPA-mediated currents we observed with FRRS1L knockdown points 
to an important role for the protein in normal AMPA receptor function whose relevance has not 
previously been appreciated. Our findings suggest that loss-of-function mutations may impair 
normal glutamatergic neurotransmission, leading to a hyperkinetic movement disorder, epilepsy, 
and a progressive course related to chronic disruption of normal neuronal circuit function.  
Mutations in another AMPA receptor outer core component, PRRT2, have been shown 
to lead to seizures and chorea in affected individuals (13). Patients with mutations in PRRT2 
generally have paroxysmal symptoms rather than a degenerative course, but such cases 
typically involve heterozygous mutations rather than the homozygous mutation we observed in 
our cases. The recent identification of patients with biallelic PRRT2 mutations suggests a more 
severe phenotype in such individuals (14). The identification of additional patients with 
mutations in FRRS1L or related AMPA receptor core proteins will help shed light on the role of 
these accessory proteins in modulating glutamatergic signaling in the central nervous system, 
whose complexities are now beginning to be unraveled (15). 
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Methods 
 Methods and associated references are available in the online version of the manuscript.  
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Figure legends 
Figure 1: Mutations in human FRRS1L and effects of loss of function on cell biology. (a) 
The two premature truncation codon mutations are predicted to lead to loss of the FRRS1L 
transmembrane domain. (b) Immunoblot in patient fibroblasts demonstrates diminished levels of 
FRRS1L in both patients with premature stop mutations compared to age and sex-matched 
controls (representative image). (c) FRRS1L expression in wild-type primary mouse neurons; a 
high degree of co-localization with GluR1 is seen (Pearson’s r= 0.70). (d) Diminished cell-
surface co-localization of FRRS1L and GluR1 in patient cell lines by total internal reflection 
fluorescence (TIRF) microscopy. (e) FRRS1L knockdown neuronally differentiated SH-SY5Y 
cells show decreased Ca2+ influx after stimulation with 100µM AMPA (representative tracing). (f) 
Mean Ca2+ influx is significantly decreased by FRRS1L knockdown (mean ± SEM; n = 30-50 
cells per condition; * p<0.05). (g) Bath applied 100µM AMPA-induced inward currents in control 
and siFRRS1L cells at holding potential = -80mV (representative tracings). (h) Current-voltage 
(I-V) curves under these conditions. (i) Mean current intensity at -80mV (mean ± SEM; n = 8-10 
recordings per condition; * p<0.05). 
 
Figure 2: Frrs1l deficiency leads to impairment of movement and early demise in mice. 
(a) Grip strength of Frrs1l tm1b/tm1b is significantly reduced (p<0.0001) when compared to 
C57BL/6NTac controls. Measurements are an average of 3 determinations of force (g) over all 4 
limbs. n = 16 C57BL/6NTac; n = 16 Frrs1l tm1b/+; n = 12 Frrs1l tm1b/tm1b. (b) Total distance 
moved in the first five minutes spent in an open field arena is significantly increased (p<0.0001) 
in Frrs1l tm1b/tm1b when compared to C57BL6/6NTac controls. n = 20 C57BL/6NTac; n = 16 
Frrs1l tm1b/+; n = 14 Frrs1l tm1b/tm1b. Error bars represent SEM for both graphs. (c) General activity 
in a viewing jar over a five minute period is increased in Frrs1l tm1b/tm1b compared to 
C57BL/6NTac controls (p<0.001). Frrs1l tm1b/tm1b show increased incidence of abnormal gait 
(p<0.0001) (d), trunk curling (e) and hindlimb grasping (p<0.0001) (f) when compared to 
C57BL/6NTac controls and Frrs1l tm1b/+ littermates. n = 20 C57BL/6NTac; n = 16 Frrs1l tm1b/+ ; n 
= 14 Frrs1l tm1b/tm1b. All data is for males and females combined, as no sex differences were 
observed. 
 
Supplemental material 
Supplemental Figure 1: Families with neurodegeneration, chorea, and progressive 
cerebral volume loss. (a) A total of 8 patients from 4 unrelated families were affected by this 
progressive neurological disease. (b) Diffuse cortical and cerebellar volume loss is seen by 
brain MRI (long arrows), with ex vacuo ventriculomegaly and flattening of the heads of the 
caudate nuclei (arrows) and periventricular fluid attenuation inversion recovery (FLAIR) 
hyperintense signal (arrowheads). 
  
Supplemental Figure 2: Frrs1l expression pattern. (a) Murine Frrs1l expression detected by 
lacZ reporter at times indicated. Frrs1l is expressed throughout the adult brain, predominantly in 
cerebellum (a), differentially throughout layers of the cortex (b), thalamus (c), hippocampus (d) 
substantia nigra (e) and anterior olfactory nucleus (f). There is expression in the dorsal horn of 
the lumbar spinal cord (g), and the trigeminal ganglion (h). Outside of the nervous system, 
Frrs1l is expressed in the testis and epididymis (i) and seminiferous tubules (j). During 
development (E12.5) Frrs1l is expressed in the ventral forebrain (k) and weakly in the spinal 
cord (l). (b) RT-PCR shows similar amounts of FRRS1L transcript in both c.961C>T and 
c.845G>A patient cells when compared to controls (representative image from n = 3 
experiments). 
 
Supplemental Figure 3: Immunofluorescence studies in patients and controls. (a) Mutant 
FRRS1L did not mislocalize to alternate intracellular compartments. (b) FRRS1L patient 
fibroblasts do show diminished cell surface localization of the protein by total internal reflection 
fluorescence microscopy (TIRF) (representative images from 3-5 experiments per condition).  
 
Supplemental Figure 4: FRRS1L knockdown in SH-SY5Y cells. FRRS1L protein levels 
relative to control are similar to those seen in patient fibroblasts (n = 3); transient receptor 
potential channel 1 and actin serve as loading controls. 
 
Supplemental Figure 5: Construction and validation of the Frrs1l tm1b/tm1b mouse. (a) 
Schematic depicting the construction of the Frrs1l null mouse using a knockout-first-reporter 
tagged insertion allele vector (www.i-dcc.org/imits/targ_rep/alleles/14093/vector-image) (b) 
Sequence alignment based on Sanger sequencing verifying effective loss of exon 3 (www.i-
dcc.org/imits/targ_rep/alleles/14093/targeting-vector-genbank-file). (c) Southern blot for 
FRRS1L-TM1A showing expected bands indicating that the 5’ (12.6kb; Mfel) and 3’ (19.2kb; 
BstE11) ends of the construct, respectively, are correctly positioned and intact. (d) Immunoblot 
depicting dose-response of Frrs1l protein levels in wild-type, heterozygous and homozygous 
animals (representative image). 
 
Supplemental Figure 6: Neuropathological analysis of Frrs1l knockout mice. Hematoxylin 
& eosin stain shows normal cortical, basal ganglia and cerebellar architecture without evidence 
of cortical atrophy (representative images). 
 
Supplemental Table 1. Clinical features of FRRS1L patients 
 
Supplemental Table 2. Regions of homozygosity shared by index family members 
 
Supplemental Table 3. Sequence variants identified in a cohort of Huntington disease- 
like patients lacking triplet repeat expansions in HTT 
 
Supplementary Table 4. Survival of wild-type vs. Frrs1l tm1b/tm1b mice 
 
Supplemental Video 1: Affected patient from family 2 demonstrating generalized chorea 
 
Supplemental Video 2: Frrs1l tm1b/tm1b mice exhibit abnormal hyperkinetic movements (a) 
compared to wild-type controls (b) 
Patients The index family hailed from southern Saudi Arabia. The parents were distant 
cousins. All five of the couple’s children developed progressive chorea, dementia and epilepsy. 
One child (patient 1_II-2) had already succumbed to the disease at the time of ascertainment. 
All children were born at term without complications. All had normal early development, but 
began to regress between the ages of 18-22 months, ceasing to walk and losing expressive 
language. This coincided with the onset of hemiclonic and tonic-clonic seizures with some 
response to carbamazepine and/or valproate.  Examinations disclosed no dysmorphic features, 
normal fundi, global developmental delay, diffuse hypotonia, and generalized chorea with a 
paucity of volitional movement. All of the affected children became less responsive to the 
environment over time, and their hyperkinetic movement disorder gradually gave way to a rigid, 
akinetic state in late adolescence.  
 Patient 2_II-1, an unrelated girl, was born to non-consanguineous Caucasian parents 
after an unremarkable pregnancy at 31 weeks gestation. At 4 months of age, she started having 
choreoathetotic movements of her hands, opisthotonic posturing and occasional hand tremors. 
She gained developmental motor and language milestones until age 13 months, when she 
began to have generalized tonic-clonic seizures. During periods of illness, her seizures were 
accompanied by chaotic eye movements and forced gaze deviation, frequent episodes of loss 
of tone, fluctuating levels of alertness, and truncal hypotonia. Between 14 and 27 months of 
age, her seizures remained refractory to levetiracetam, phenobarbital, clobazam and the 
ketogenic diet. This was associated with developmental regression. Her examination was 
significant for generalized chorea and ballism (Video 1).   
 Patient 3_II-1 was a Puerto Rican girl with no recognized consanguinity born at 37 
weeks estimated gestational age. She cruised with an ataxic gait beginning at 11 months and 
used several words appropriately before experiencing a neurodevelopmental regression at age 
24 months. She developed juvenile spasms and was later diagnosed with Lennox-Gastaut 
syndrome. She initially benefited from the ketogenic diet, but her seizures were never fully 
controlled. Examination revealed horizontal and vertical nystagmus with esotropia, generalized 
chorea and cogwheel rigidity of her upper limbs, hyperreflexia, hypotonia, and diminished 
volitional movement (she did not reach purposefully or have a means of locomotion). No 
expressive language was evident.  
 Patient 4_II-1, an unrelated girl, was born at term by caesarean section to 
consanguineous Moroccan parents after a pregnancy complicated by gestational diabetes. Poor 
muscle tone was noted from early infancy, and she has never attained good head control. She 
was delayed in reaching early motor milestones. At age 10 months, she could fix and follow 
objects, albeit with saccadic pursuit, and could grasp nearby objects and bring them to her 
mouth. She demonstrated choreoathetoid movements of her arms and hands. Her alertness 
fluctuated, putatively related to hypomotor seizures. These proved resistant to levetiracetam, 
valproic acid and vigabatrin, and her eye contact and muscle tone deteriorated. At age 17 
months, she was admitted with status epilepticus. Phenobarbital led to satisfactory seizure 
control, and she has now mainly short, multifocal clonic seizures and intermittent myoclonus. 
She is currently fed via nasogastric tube. 
 
Homozygosity mapping & parametric linkage analysis  Genomic DNA was extracted 
from whole blood, and regions of homozygosity shared by affected individuals but absent in 
unaffected individuals in family 1 were identified using Affymetrix Whole-Genome CytoScan® 
HD single nucleotide polymorphism (SNP) arrays according to the manufacturer’s instructions. 
MERLIN was used to calculate LOD scores. 
 
Exome analysis  Exonic targets were enriched with the SeqCap EZ Human Exome 
Library v3.0 kit (Nimblegen) and sequencing was performed on an Illumina HiSeq2000 or 2500 
according to the manufacturer’s instructions in order to generate paired-end reads. Average 
coverage depth was >70× within the targeted exome. Sequencing reads were aligned to the 
NCBI human reference genome (GRCh37/hg19) using the Burrow-Wheeler Aligner (BWA 
0.7.10). Picard Tools (1.111) was subsequently used for sorting and marking duplicates. Local 
realignment, base quality score recalibration, and variant calling was performed using the 
Genome Analysis Toolkit (GATK 3.3-0) and variant call files were evaluated using NextCode 
(Cambridge, MA) or Cartagenia Bench Lab NGS software (Cambridge, MA). Filtering was 
performed by removing low-quality calls (Illumina threshold <20) and excluding variants with an 
MAF >0.01 based on the ExAc Browser and Exome Variant Server databases while prioritizing 
homozygous variants predicted deleterious by SIFT, Polyphen-2, MutationTaster and CADD.   
 
Sanger sequence analysis Variants identified by whole exome sequencing were confirmed by 
Sanger sequencing. Primers (sequences available upon request) were designed to span intron-
exon boundaries of NM_014334. 
 
Cells Primary fibroblast lines were established from 3mm circular punch biopsies and 
confirmed mycoplasma-free. Patient and age-matched control cells of equivalent early passage 
number were grown in Dulbecco's modified Eagle's medium (DMEM; ThermoFisher), 
supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin and 50 µg/ml 
streptomycin. SH-SY5Y cells were obtained from the American Type Culture Collection 
(Manassas, VA), cultured in DMEM, and neuronally differentiated by growth in DMEM + 10µM 
retinoic acid for 7 days. 
 
Antibodies Antibodies included anti-FRSS1L (Atlas, 1:1000 for WB and 1:100 for IF), anti-
Na/K ATPase (Abcam, 1:100 for IF), anti-GM130 (BD Biosciences, 1:100 IF), anti-EEA1 (Sigma, 
1:100 IF), and anti-GluR1 (Cell Signaling, 1:100 for IF), anti-calnexin (Abcam, 1:100 for IF), anti-
TRPC1 (Alomone labs, 1:500 WB); anti-β-actin (Santa Cruz Biotechnology, 1:1000 WB). 
 
Transfections SH-SY5Y cells (1.5x105 cells/ml) were transfected with FRRS1L siRNA or 
scrambled control siRNA (Ambion) using RNAiMax reagent (Ambion). 
 
Calcium Measurements Neuronally-differentiated SH-SY5Y cells were incubated with 2 μM 
fura-2 (Molecular Probes) for 45 min and washed twice with Ca2+-free standard external solution 
(10 mM HEPES, 120 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 10 mM glucose, pH 7.4). 
Fluorescence intensity of Fura-2-loaded cells was monitored with a CCD camera-based imaging 
system and analyzed using PCI software (Compix, Cranberry, PA), to provide ratios of Fura-2 
fluorescence at 340 nm excitation to that of 380 nm excitation (F340/F380).  
 
Electrophysiology For patch clamp experiments, coverslips with neuronally-differentiated 
SH-SY5Y cells were perfused with Ringer's solution (145mM NaCl, 5mM KCl, 1mM MgCl2, 
1mM CaCl2, 1 µM tetrodotoxin (TTX), 10mM HEPES, 10mM Glucose, pH 7.3). Whole cell 
currents were recorded using an Axopatch 200B (Molecular Devices, Sunnyvale, CA) and a 
patch pipette filled with standard intracellular solution (145 mM CsCl, 0.1 mM CaCl2, 2 mM 
MgCl2, 1 mM, EGTA, and 5 mM HEPES, pH 7.2). With holding potential = -60mV, voltage 
ramps ranging from -100mV to +100mV and 100ms duration were delivered at 2s intervals after 
whole cell configuration was formed. Basal leak was subtracted from final currents. 
 
Microscopy Patient-derived fibroblasts and controls were grown to near-confluence, washed 
twice, fixed in 4% paraformaldehyde, permeabilized with PBS/0.1% Triton X-100 and labeled 
with primary antibody and visualized with secondary antibody. Cells were visualized using the 
100X objective of  an A1 confocal microscope (Nikon, Melville, NY) equipped with an Andor 
iXon 897 (Andor Technologies Ltd., Belfast, UK) for total internal reflection fluorescence (TIRF) 
imaging.    
 
Immunoblotting Cell contents were released using lysis buffer (25mM Tris-HCl pH 7.6, 
150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, and Roche complete protease 
inhibitor). Protein concentration was determined by BCA assay (Pierce). Protein extracts were 
separated by 12% SDS-PAGE under reducing conditions, transferred to PVDF membranes and 
probed with primary antibodies. 
 
Mice All experiments were performed under license from the UK Home Office (30/2890) and 
local Animal Welfare and Ethical Review Body approval. All animals were bred and maintained 
on site. The Frrs1l tm1b(EUCOMM)Hmgu mice were generated at MRC Harwell which distributes these 
mice on behalf of the European Mouse Mutant Archive (www.infrafrontier.eu) using the 
knockout first method (1, 2, 3). Funding and associated primary phenotypic information may be 
found at www.mousephenotype.org. Mice were housed on a 12:12 light dark cycle with free 
access to water and fed ad libitum with RM3 (SDS). Frrs1 ltm1a(EUCOMM)Hmgu mice were derived 
from C57BL6/NTac ES cells. The null allele, Frrs1ltm1b(EUCOMM)Hmgu, was created by carrying out 
an IVF using Frrs1ltm1a/+ sperm and C57BL6/NTac oocytes. Soluble cell permeable cre (TAT-Cre 
(Tat-NLS-Cre, HTNC, HTNCre), Excellegen, Rockville, USA) was added to two cell 
Frrs1ltm1a/+ embryos to convert them to Frrs1ltm1b/+. The addition of cre excised the selection 
cassette and exon 3 of the Frrs1l gene, creating a lacZ tagged null allele. Following washing to 
remove soluble cre, the IVF procedure was completed. The Frrs1ltm1b/+ offspring were crossed to 
C57BL/6NTac and then intercrossed to create Frrs1ltm1b/+and Frrs1ltm1b/tm1b. 
 
Open field Mice were placed in square arenas made of grey perspex (44x44cm) at lux of 
150-200. Mice were allowed to explore the arenas for 20 minutes whilst tracking was recorded 
by Ethovision XT software (Noldus, Netherlands). Arenas were divided into periphery and center 
zones and parameters such as time moving, distance moved and duration in zone were 
calculated. For a full list of parameters 
see https://www.mousephenotype.org/impress/protocol/81/7.     
 
Grip strength Mice were held by their tail and placed on a grip strength apparatus (Bioseb, 
France) before being pulled down the grid and grip strength recorded. Each mouse completed 
three trials for forepaws and three trials for combined fore and hindpaws. Data across the three 
trials were averaged.  
 
Combined SHIRPA and dysmorphology Mice were observed for behavioral changes using a 
modified SHIRPA protocol (4). Briefly, mice were placed on a wire grid in a viewing jar (height 
15 cm, diameter 11 cm), where they were observed for five minutes for general activity and 
behavior. Mice were then transferred to an arena (55 x 33cm) for observations of motor 
behaviors. Finally mice were handled to detect phenotypes including dysmorphic abnormalities, 
trunk curling and limb grasping. A full list of parameters can be found 
at https://www.mousephenotype.org/impress/protocol/186/7.  
 
Statistical analysis Continuous data was analyzed using Students t-test while categorical 
data was analyzed using Fisher’s exact test. A chi squared test was carried out to determine the 
significance of deviation from normal Mendelian ratios. Statistical analysis was carried out using 
GraphPad Prism 6 and R version 3.2.2 and R Studio version 0.99.485 and the following 
conventions were used: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001. 
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Supplementary Table 1: Clinical features of FRRS1L patients 
 
Patient Mutation Age at 
onset 
Reg-
ression 
Intellectual 
impairment 
Movement 
disorder 
Epilepsy Neuromotor Other 
1_II-1 (p.G321*) 18 
months 
Yes Severe; no 
expressive 
speech 
Chorea; later 
rigidity, 
hypokinesia 
Focal Spasticity; 
impaired  
volitional 
movement 
 
 
1_II-2 (p.G321*) 22 
months 
Yes Severe; no 
expressive 
speech 
Chorea; later 
rigidity, 
hypokinesia 
Hemiclonic 
seizures; 
later 
generalized 
Spasticity; 
impaired  
volitional 
movement 
 
Died at age 
16 
1_II-3 (p.G321*) 22 
months 
Yes Severe; no 
expressive 
speech 
Chorea; later 
rigidity, 
hypokinesia 
Hemiclonic 
seizures 
Spasticity; 
impaired  
volitional 
movement 
 
 
1_II-4 (p.G321*) 23 
months 
Yes Severe; no 
expressive 
speech 
Chorea; later 
rigidity, 
hypokinesia 
 Spasticity; 
impaired  
volitional 
movement 
 
1_II-5 (p.G321*) 24 
months 
No Severe; no 
expressive 
speech 
Chorea Hemiclonic 
seizures 
  
         
2_II-1 (p.W282*) 4 months No Severe; no 
expressive 
speech 
Chorea, 
ballism 
Multifocal; 
intractable 
Hypotonia; 
impaired 
volitional 
movement 
 
         
3_II-1 (p.G246del) 24 
months 
Yes Severe; no 
expressive 
speech 
Chorea; 
cogwheel 
rigidity 
Juvenile 
Spasms/ 
Lennox-
Gastaut 
Hypotonia; 
impaired 
volitional 
movement 
Horizontal & 
vertical 
nystagmus 
4_II-2 (p.Ile146Asn 
fs*10) 
  Severe; no 
expressive 
speech 
Chorea; 
myoclonus 
   
 
 Chromosome Start End Size (Mb) 
1 147,779,938 151,347,700 3.5 
3 62,613 4,878,792 4.8 
9 104,622,396 119,149,440 14.5 
16 31,901,547 35,220,544 3.3 
X 61,932,503 65,386,406 3.5 
 
 
Rare heterozygous FRRS1L variants in a cohort of 202 patients with mixed movement 
disorders (ataxia, spastic paraplegia, dystonia, parkinsonism, etc.) and neurodegeneration 
FRRS1L 
variant 
 ESP6500 ExAc Phenotype 
c.T469A; 
(p.C157S) 
 - 8.13E-06 
 
Ataxia, optic nerve atrophy 
c.721delG; 
(p.A241fs) 
 - 8.13E-06 Multiple system atrophy 
c.T686C; 
(p.V229A) 
 0.000231 7.40E-04 Ataxia 
c.A885G; 
(p.I295M) 
 0.000077 1.63E-05 Multiple system atrophy 
 
 
Survival at E18.5 and P21 
Age Frrs1l +/+ Frrs1l +/- Frrs1l -/- 
E18.5 6 26 13 
3 weeks 60 101 16 
 
 
